692 related articles for article (PubMed ID: 8880858)
21. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
22. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay.
Wettstein JG; Grouhel A
Pharmacol Biochem Behav; 1996 Feb; 53(2):411-6. PubMed ID: 8808151
[TBL] [Abstract][Full Text] [Related]
23. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons.
Hauser KF; Foldes JK; Turbek CS
Exp Neurol; 1999 Dec; 160(2):361-75. PubMed ID: 10619553
[TBL] [Abstract][Full Text] [Related]
24. Blockade of the development of morphine tolerance by U-50,488, an AVP antagonist or MK-801 in the rat hippocampal slice.
Su MT; Lin WB; Lue WM; Cheng CY; Tao PL
Br J Pharmacol; 1998 Feb; 123(4):625-30. PubMed ID: 9517380
[TBL] [Abstract][Full Text] [Related]
25. Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception.
Stevenson GW; Folk JE; Linsenmayer DC; Rice KC; Negus SS
J Pharmacol Exp Ther; 2003 Dec; 307(3):1054-64. PubMed ID: 14557380
[TBL] [Abstract][Full Text] [Related]
26. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.
Schoffelmeer AN; Hogenboom F; Mulder AH
Br J Pharmacol; 1997 Oct; 122(3):520-4. PubMed ID: 9351509
[TBL] [Abstract][Full Text] [Related]
27. Co-treatment with MK-801 potentiates naloxone-precipitated morphine withdrawal in the isolated spinal cord of the neonatal rat.
Bell JA; Beglan CL
Eur J Pharmacol; 1995 Dec; 294(1):297-301. PubMed ID: 8788444
[TBL] [Abstract][Full Text] [Related]
28. The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices.
Lue WM; Su MT; Lin WB; Tao PL
Eur J Pharmacol; 1999 Oct; 383(2):129-35. PubMed ID: 10585526
[TBL] [Abstract][Full Text] [Related]
29. Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.
Negus SS; Morrissey EM; Rosenberg M; Cheng K; Rice KC
Psychopharmacology (Berl); 2010 Jun; 210(2):149-59. PubMed ID: 20101391
[TBL] [Abstract][Full Text] [Related]
30. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
31. Intrathecal high-dose morphine induces spinally-mediated behavioral responses through NMDA receptors.
Sakurada T; Watanabe C; Okuda K; Sugiyama A; Moriyama T; Sakurada C; Tan-No K; Sakurada S
Brain Res Mol Brain Res; 2002 Jan; 98(1-2):111-8. PubMed ID: 11834301
[TBL] [Abstract][Full Text] [Related]
32. Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig.
Culpepper-Morgan JA; Holt PR; LaRoche D; Kreek MJ
Life Sci; 1995; 56(14):1187-92. PubMed ID: 7475895
[TBL] [Abstract][Full Text] [Related]
33. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
34. The specific N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 blocks U-50,488, but not morphine antinociception.
Kest B; Marek P; Liebeskind JC
Brain Res; 1992 Aug; 589(1):139-42. PubMed ID: 1422813
[TBL] [Abstract][Full Text] [Related]
35. MK-801 blocks the expression but not the development of tolerance to morphine in the isolated spinal cord of the neonatal rat.
Bell JA; Beglan CL
Eur J Pharmacol; 1995 Dec; 294(1):289-96. PubMed ID: 8788443
[TBL] [Abstract][Full Text] [Related]
36. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance.
Manning BH; Mao J; Frenk H; Price DD; Mayer DJ
Pain; 1996 Sep; 67(1):79-88. PubMed ID: 8895234
[TBL] [Abstract][Full Text] [Related]
37. Actions of opioids on excitatory and inhibitory transmission in substantia gelatinosa of adult rat spinal cord.
Kohno T; Kumamoto E; Higashi H; Shimoji K; Yoshimura M
J Physiol; 1999 Aug; 518 ( Pt 3)(Pt 3):803-13. PubMed ID: 10420016
[TBL] [Abstract][Full Text] [Related]
38. N-methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development.
Elliott K; Kest B; Man A; Kao B; Inturrisi CE
Neuropsychopharmacology; 1995 Dec; 13(4):347-56. PubMed ID: 8747759
[TBL] [Abstract][Full Text] [Related]
39. Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphé nucleus in vitro.
Pinnock RD
Brain Res; 1992 Jun; 583(1-2):237-46. PubMed ID: 1354563
[TBL] [Abstract][Full Text] [Related]
40. The role of nitric oxide in the development of opioid withdrawal induced by naloxone after acute treatment with mu- and kappa-opioid receptor agonists.
Capasso A; Sorrentino L; Pinto A
Eur J Pharmacol; 1998 Oct; 359(2-3):127-31. PubMed ID: 9832382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
